Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01403_DB08919_nanopub.RA1nVpd66qcxnzhHPfMnwa7dG30L4ryNYR7w9I56cLuIo#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01403_DB08919 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01403_DB08919 label "DDI between Methotrimeprazine and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed. [drugbank_resource:DB01403_DB08919]" assertion.
- drugbank_resource:DB01403_DB08919 identifier "drugbank_resource:DB01403_DB08919" assertion.
- drugbank_resource:DB01403_DB08919 title "DDI between Methotrimeprazine and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed." assertion.
- drugbank:DB08919 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01403_DB08919 assertion.
- drugbank:DB01403 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01403_DB08919 assertion.